These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 23236065)
21. Isolation and characterization of a highly attenuated respiratory syncytial virus (RSV) vaccine candidate by mutagenesis of the incompletely attenuated RSV A2 ts-1 NG-1 mutant virus. Hsu KH; Crowe JE; Lubeck MD; Davis AR; Hung PP; Chanock RM; Murphy BR Vaccine; 1995 Apr; 13(5):509-15. PubMed ID: 7543716 [TBL] [Abstract][Full Text] [Related]
22. Enhancing the Thermostability and Immunogenicity of a Respiratory Syncytial Virus (RSV) Live-Attenuated Vaccine by Incorporating Unique RSV Line19F Protein Residues. Rostad CA; Stobart CC; Todd SO; Molina SA; Lee S; Blanco JCG; Moore ML J Virol; 2018 Mar; 92(6):. PubMed ID: 29263264 [TBL] [Abstract][Full Text] [Related]
23. Attenuation of the recombinant human parainfluenza virus type 3 cp45 candidate vaccine virus is augmented by importation of the respiratory syncytial virus cpts530 L polymerase mutation. Skiadopoulos MH; Surman SR; St Claire M; Elkins WR; Collins PL; Murphy BR Virology; 1999 Jul; 260(1):125-35. PubMed ID: 10405364 [TBL] [Abstract][Full Text] [Related]
24. Evaluation of recombinant respiratory syncytial virus gene deletion mutants in African green monkeys for their potential as live attenuated vaccine candidates. Jin H; Cheng X; Traina-Dorge VL; Park HJ; Zhou H; Soike K; Kemble G Vaccine; 2003 Sep; 21(25-26):3647-52. PubMed ID: 12922094 [TBL] [Abstract][Full Text] [Related]
25. Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective. Boyoglu-Barnum S; Todd SO; Meng J; Barnum TR; Chirkova T; Haynes LM; Jadhao SJ; Tripp RA; Oomens AG; Moore ML; Anderson LJ J Virol; 2017 May; 91(10):. PubMed ID: 28275196 [TBL] [Abstract][Full Text] [Related]
26. The live attenuated subgroup B respiratory syncytial virus vaccine candidate RSV 2B33F is attenuated and immunogenic in chimpanzees, but exhibits partial loss of the ts phenotype following replication in vivo. Crowe JE; Randolph V; Murphy BR Virus Res; 1999 Jan; 59(1):13-22. PubMed ID: 10854162 [TBL] [Abstract][Full Text] [Related]
27. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector. Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977 [TBL] [Abstract][Full Text] [Related]
28. Altered growth characteristics of recombinant respiratory syncytial viruses which do not produce NS2 protein. Teng MN; Collins PL J Virol; 1999 Jan; 73(1):466-73. PubMed ID: 9847352 [TBL] [Abstract][Full Text] [Related]
29. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. Karron RA; Wright PF; Belshe RB; Thumar B; Casey R; Newman F; Polack FP; Randolph VB; Deatly A; Hackell J; Gruber W; Murphy BR; Collins PL J Infect Dis; 2005 Apr; 191(7):1093-104. PubMed ID: 15747245 [TBL] [Abstract][Full Text] [Related]
30. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F. Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of the Safety and Immune Efficacy of Recombinant Human Respiratory Syncytial Virus Strain Long Live Attenuated Vaccine Candidates. Wang LN; Peng XL; Xu M; Zheng YB; Jiao YY; Yu JM; Fu YH; Zheng YP; Zhu WY; Dong ZJ; He JS Virol Sin; 2021 Aug; 36(4):706-720. PubMed ID: 33559831 [TBL] [Abstract][Full Text] [Related]
32. New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Collins PL; Murphy BR Proc Am Thorac Soc; 2005; 2(2):166-73. PubMed ID: 16113487 [TBL] [Abstract][Full Text] [Related]
33. Satisfactorily attenuated and protective mutants derived from a partially attenuated cold-passaged respiratory syncytial virus mutant by introduction of additional attenuating mutations during chemical mutagenesis. Crowe JE; Bui PT; London WT; Davis AR; Hung PP; Chanock RM; Murphy BR Vaccine; 1994 Jun; 12(8):691-9. PubMed ID: 8091846 [TBL] [Abstract][Full Text] [Related]
34. Refining the balance of attenuation and immunogenicity of respiratory syncytial virus by targeted codon deoptimization of virulence genes. Meng J; Lee S; Hotard AL; Moore ML mBio; 2014 Sep; 5(5):e01704-14. PubMed ID: 25249281 [TBL] [Abstract][Full Text] [Related]
36. A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes. Whitehead SS; Firestone CY; Collins PL; Murphy BR Virology; 1998 Aug; 247(2):232-9. PubMed ID: 9705916 [TBL] [Abstract][Full Text] [Related]
37. A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge. Wang D; Phan S; DiStefano DJ; Citron MP; Callahan CL; Indrawati L; Dubey SA; Heidecker GJ; Govindarajan D; Liang X; He B; Espeseth AS J Virol; 2017 Jun; 91(11):. PubMed ID: 28298602 [TBL] [Abstract][Full Text] [Related]
38. Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines in vitro, and is attenuated and induces protective immunity in calves. Taylor G; Wyld S; Valarcher JF; Guzman E; Thom M; Widdison S; Buchholz UJ J Gen Virol; 2014 Jun; 95(Pt 6):1244-1254. PubMed ID: 24700100 [TBL] [Abstract][Full Text] [Related]
39. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein. Elliott MB; Pryharski KS; Yu Q; Boutilier LA; Campeol N; Melville K; Laughlin TS; Gupta CK; Lerch RA; Randolph VB; LaPierre NA; Dack KM; Hancock GE J Virol; 2004 Aug; 78(16):8446-54. PubMed ID: 15280453 [TBL] [Abstract][Full Text] [Related]
40. Rescue of codon-pair deoptimized respiratory syncytial virus by the emergence of genomes with very large internal deletions that complemented replication. Le Nouën C; McCarty T; Yang L; Brown M; Wimmer E; Collins PL; Buchholz UJ Proc Natl Acad Sci U S A; 2021 Mar; 118(13):. PubMed ID: 33753491 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]